Obagi Medical has released significant clinical data regarding its hyaluronic acid injectables and Nu-Cil scalp treatment during the American Society for Dermatologic Surgery (ASDS) Annual Meeting held from November 13 to 16, 2025, in Chicago, Illinois. This announcement highlights the company’s continued commitment to innovation in physician-dispensed skincare and aesthetic solutions.
At the ASDS event, a pivotal study comparing two hyaluronic acid fillers for midface augmentation was presented. The study particularly focused on the improvement in the appearance of nasolabial folds, a common area of concern for many seeking aesthetic treatments. This research was recognized as one of the top ten abstracts presented at the conference, underscoring its importance in the field of dermatology.
Dr. Sue Ellen Cox, an influential figure in the dermatologic community, led the presentation of the study. Her findings contribute to the growing body of evidence supporting the effectiveness of Obagi’s hyaluronic acid injectables. This recognition not only elevates the profile of the products but also reinforces Obagi’s role as a leader in aesthetic solutions.
Obagi Medical’s innovative approach combines rigorous scientific research with practical applications in the field. The company, which is part of Waldencast plc (NASDAQ: WALD), continues to set high standards for safety and efficacy in its skincare offerings. Through this recent data, Obagi aims to enhance the understanding of hyaluronic acid’s benefits among both practitioners and patients.
The presentation at the ASDS Annual Meeting reflects a broader trend in the skincare industry, where evidence-based findings are becoming increasingly crucial. As the market for aesthetic treatments grows, the demand for substantiated clinical data becomes paramount. Obagi’s efforts to share these insights demonstrate its proactive stance in addressing consumer needs and fostering trust within the medical community.
This new data marks a pivotal moment for Obagi Medical as it seeks to expand its reach in the aesthetic market. The company remains focused on research and development, continuously exploring new avenues to improve patient outcomes and satisfaction. With the backing of compelling clinical data, Obagi is well-positioned to navigate the competitive landscape of skincare and aesthetic solutions.
The findings presented by Dr. Cox not only highlight the potential of Obagi’s products but also signify a commitment to ongoing research and innovation in the dermatologic field. As the industry evolves, Obagi Medical is poised to remain at the forefront, advancing both technology and patient care.
